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Summary
Background: Basal cell cancer is a common skin cancer,
yet studies of second tumors after Hodgkin’s disease tend
to exclude basal cell cancers as second malignant tumors
from analysis. Basal cell carcinomas (BCC) are possibly
more common in immunosuppressed patients and were
recently implicated as indicators of subsequent malignan-
cies. Materials and Methods: Our database of 1,120 pa-
tients with Hodgkin’s disease (derived from the tumor
registry) was investigated for the occurrence of later
BCCs. Kaplan-Meier curves were calculated. Results: A
total of 9 cases of BCC were observed 0–20 years after
the diagnosis of Hodgkin’s disease. One case relapsed
after excision. The probability of second BCC was 2.1%
after 15 years of follow-up and 7.1% after 20 years. Sta-
tistically, the risk for second BCC was increased only in
younger patients and with prolonged follow-up, but not
in the total group of patients with Hodgkin’s disease.
Conclusion: BCC is not a major threat for the survivors of
Hodgkin’s disease, but continued follow-up is necessary.
Schlüsselwörter
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Zusammenfassung
Einleitung: Basaliome sind häufige Hauttumoren und
wurden bis jetzt in den meisten Studien der Zweitneo-
plasien nach Morbus Hodgkin ausgeschlossen. Basaliome
haben möglicherweise eine erhöhte Inzidenz bei immun-
supprimierten Patienten, und wurden kürzlich als Indika-
tor-Neoplasien für nachfolgende andere Tumoren be-
schrieben. Material und Methoden: Wir untersuchten
unsere Datenbasis von 1120 Patienten mit M. Hodgkin 
auf das Auftreten von späteren Basaliomen. Kaplan-
Meier-Kurven wurden errechnet. Ergebnisse: Insgesamt
konnten wir 9 Fälle von Basaliomen 0–20 Jahre nach der
Diagnose M. Hodgkin beobachten. Die Wahrscheinlichkeit
des Auftretens von Zweitbasaliomen beträgt 2,1% nach
15 Jahren Nachsorge und 7,1% nach 20 Jahren. Gegen-
über einem Normalkollektiv war das Auftreten von Basa-
liomen nur bei jüngeren Patienten und bei sehr langer
Nachsorge erhöht, nicht jedoch im Gesamtkollektiv der
Patienten mit M. Hodgkin. Schlußfolgerung: Basaliome
gehören nicht zu den häufigsten Zweittumoren nach 
M. Hodgkin. Jedoch ist eine weitere Überwachung der
Patienten, auch auf das Auftreten von Basaliomen,
erforderlich.
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Introduction
Patients treated for Hodgkin’s disease have an increased risk to
develop second malignant neoplasms. This risk correlates with
age, stage of Hodgkin’s disease, the treatment received, sple-
nectomy, and certain other factors such as impaired immunity.
At 15 years, a cumulative risk in the range of 11–18% to develop
second malignant neoplasms was observed in different case
series [for review see 1]. Basal cell carcinoma (BCC) is a fre-
quent malignant tumor of the skin which rarely metastasizes.
BCCs are associated with increasing age, exposure to sun light,
and ionizing radiation [2]. An increased incidence of BCC was
suggested in patients with AIDS [3]. In a case report, metastatic
BCC was described in a patient infected with HIV [4]. More re-
cently, BCCs were also described as predictors for other cancers
such as non-Hodgkin’s lymphomas, leukemias and carcinomas
[5] and for malignant melanomas [6]. In several case series of sec-
ond malignant tumors occurring after Hodgkin’s disease, BCCs
were either not mentioned [7–10] or excluded from analysis [11,
12].We therefore investigated the incidence and the characteris-
tics of BCCs in our database of 1,120 patients with Hodgkin’s
disease treated at 5 centers in Munich between 1976 and 1994.
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Materials and Methods
Starting from the database of the Munich tumor registry, 1,120 patients
with the diagnosis of Hodgkin’s disease treated at 5 hematology centers
and the Department of Radiation Oncology were investigated for the
development of second malignant tumors. All patients’ files were re-
viewed, and details of the medical history and personal as well as profes-
sional health risks were analyzed. Concerning Hodgkin’s disease, special
interest was given to the date of diagnosis, exact staging, the histological
subtype as well as staging procedures, e.g. splenectomy. In addition, dura-
tion and dose of radio- and chemotherapy, time to complete remission,
time of relapse, further treatment and last follow-up were recorded. Com-
plete follow-up was achieved by contacting either the patients or the
treating physicians. In all cases, the patients or the physicians were asked
if second tumors, especially secondary skin tumors had developed.
The 1,120 patients had a total follow-up of 10,116 years with a median
follow-up of about 8 years. The median age at diagnosis was 31 years,
ranging from 2 to 84 years. 55.8% of the patients were male. In the entire
group of patients no cases of second spinal cell cancer and 2 cases of
malignant melanoma were recorded.
The calculation of the expected number of BCCs was made on the basis of
the incidence rates for the ICD (International Classification of Diseases)
code 173 of the WHO where all non-melanoma skin cancers are registered.
The incidence data are extracted from the 1993 report of the population-
based Cancer Registry of Saarland (cancer registry in Southwestern
Germany).
The comparison of the actual with the expected number of cases were
made using the standardized incidence ratio (SIR). Assuming a Poisson
distribution of the observed cancer events, 95% confidence intervals (CI)
were calculated [13] for the decision whether or not SIR is statistically
different from 1, i.e. whether or not the observed and the expected number
of BCCs are statistically different. Kaplan-Meier analysis was performed
according to standard methods.
Results and Discussion
A total of 9 cases of BCCs was recorded in our database 
of 1,120 patients treated for Hodgkin’s disease (5 males and 
4 females, for details see table 1). There were two groups of
patients: in 6 patients the second malignancy was diagnosed at
a rather young age (30–48 years), whereas in 3 patients the
second malignancy was diagnosed at the usual age for BCCs
(50–68 years). Most patients had mantle field irradiation, and
most BCCs were located on the trunk and therefore in the field
of previous radiotherapy. One patient had a BCC at the right
earlobe which was not directly included in the previous radia-
tion field. In one patient the diagnosis of BCC was coinciden-
tal to the diagnosis of Hodgkin’s disease and therefore not
related to any previous treatment for Hodgkin’s disease. In
another case, BCC was diagnosed 18 months after breast
cancer and therefore has to be considered as a third malignancy.
In no case metastatic basal cell cancer developed. One patient
had a relapse of his basal cell cancer which was again treated
by local excision. As can be seen from table 1, BCC occurred
0–20 years after the diagnosis of Hodgkin’s disease (mean
interval 13.7 years). Kaplan-Meier analysis showed a proba-
bility of developing second BCC of 0.1% after 10 years, of 
2.1% after 15 years and of 7.1% after 20 years.
With respect to the distributions of sex, age and calendar
period of our patient cohort the expected number of BCCs was
calculated as 4.6. The SIR was 1.96, with 95% CI ranging from
0.89 to 3.74. Because the value 1 is in the CI of SIR, the ob-
served number of BCC did not statistically differ from the
expected.If only young patients (aged less than 40 years at diag-
nosis of BCC) are considered, in this age group a statistically
increased risk of BCC becomes apparent (SIR 10.26, CI be-
tween 3.56 and 23.99).
Taken together, in the total group of patients with Hodgkin’s
disease, no statistically significant increase of cases with BCC
was observed. However, younger patients have a low but sig-
nificant risk. BCC is a common skin cancer and often under-
reported in studies of cancer incidence. In the International
Data Base on Hodgkin’s Disease a relative risk of 3.6 for males
Patient Age 1, Age 2, Stage of Therapy BCC in Condition at last
number, yearsa yearsb Hodgkin’s for Hodgkin’s radiation follow-up
Sex disease disease field?
1, m 15 30 IIIA CM yes alive, CR (6/97)
2, f 16 30 IIA RX yes alive, CR (7/97)
3, m 22 35 IIIA CM yes alive, CR (relapse
of BCC 6/97)
4, f 24 43c IIB RX no alive, CR (1/98)
5, m 25 36 IIIA RX yes alive, CR (7/97)
6, m 28 48 IIA CM yes alive, CR (7/97)
7, m 30 50 IIA CM yes alive, CR (4/97)
8, m 52 63 IIB CM no † (pneumonia, 5/92)
9, f 67 67 IIA RX N.A. † (Hodgkin’s disease, 6/93)
a Age at the time of HD diagnosis.
b Age at the time of BCC diagnosis.
c Diagnosis of BCC within 2 years of second breast cancer.
RX = Radiotherapy; CM = combined modality; CR = complete remission.
Table 1. Cases of BCC occurring after Hodgkin’s
disease
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and 3.5 for females was reported without mentioning further
details [14]. The conclusion of our study holds true if the data-
base of Rochester, MN, USA, is taken for comparison [15].
In this population-based incidence study, a somewhat higher
incidence in the general population was reported (age-stan-
dardized incidence/100,000 white residents:175 cases for males,
124 for females). Damage to skin by ionizing irradiation has to
be taken into consideration as an etiologic factor in patients
treated for Hodgkin’s disease. In a case report, BCC was re-
ported to occur symmetrically over acromioclavicular joints
following mantle field irradiation for Hodgkin’s disease 18 years
earlier [16]. In our collection of cases, 6/8 irradiated cases also
have a similar topographic occurrence (BCC in or close to the
original irradiation field for Hodgkin’s disease). Taken to-
gether, at least in our group of patients, BCCs are until now not
generally increased after the treatment of Hodgkin’s disease.
In young individuals, BCCs are uncommon [17]. Following
treatment of Hodgkin’s disease in young patients, second
BCCs appear more frequent. In chronically immunosup-
pressed patients (recipients of kidney transplants), a 5-fold
increase in the incidence of BCC was reported [18]. In
Hodgkin’s disease, immunity is transiently defective and re-
covers following successful treatment. As mentioned above,
the risk of subsequent BCC after Hodgkin’s disease is small
and possibly limited to younger patients with more than 10 years
follow-up. The prognosis of BCC following Hodgkin’s disease
is generally good. However, the clinician should be alerted for
second skin cancer and unclear skin lesions should be biopsied
early. A longer follow-up is necessary to assess later cases of
BCC in patients irradiated for Hodgkin’s disease.
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